Melbourne, Australia, 16 June 2022: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, today announces its senior team including Executive Chair, Prof Darren Kelly, will be attending the 2022 Biotechnology Innovation Organisation International Convention (“BIO”) held between 13-16 June 2022 in San Diego, California.
OccuRx is a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. The OccuRx team will highlight their scientific advancements including their ongoing clinical development program for the lead candidate OCX063.
OccuRx has designed a platform of candidate drugs and validated the role of a novel receptor which mediates signalling pathways associated with inflammation and fibrosis. These targeted drugs have established proof of concept as potential treatments for multiple fibrotic diseases including serious and chronic conditions impacting the kidney, lung, eye, and skin. The morbidity and mortality impact of fibrotic diseases is substantial, ultimately causing 45% of all deaths globally.
OccuRx is seeking to combine these innovative therapeutics with biomarkers and genetic analysis to identify the most suitable patients for treatment. Significant breakthroughs are urgently needed in this field, addressing a market worth greater than US$15B annually.
“We’re excited to attend the first in person BIO since 2019. It’s a great opportunity for us to meet with industry leaders and discuss scientific advancements in fibrotic and inflammatory diseases.” said Professor Darren Kelly, Executive Chair of OccuRx.
Following the past two years’ conventions held in a virtual format, the 2022 conference is attracting more than 3,000 international and domestic companies from across the biotech industry, as well as many global industry leaders and top research scholars.
